Liarozole dihydrochloride

Key Product Details

Product Description

Liarozole dihydrochloride is a cytochrome P450 inhibitor. Inhibits several cytochrome P450 enzymes including aromatase (CYP19) and retinoic acid 4-hydroxylase (CYP26). Blocks retinoic acid metabolism (retinoic acid metabolism blocking agent, RAMBA). Displays antitumor activity against androgen-dependent and independent rat prostate carcinomas.

Product Specifications for Liarozole dihydrochloride

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Liarozole dihydrochloride

The following data is based on the product molecular weight 381.69.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.62 mL	13.10 mL	26.20 mL
5 mM	0.52 mL	2.62 mL	5.24 mL
10 mM	0.26 mL	1.31 mL	2.62 mL
50 mM	0.05 mL	0.26 mL	0.52 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 6 publications citing the usage of this product.

• Njar Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg.Med.Chem. 2006 PMID: 16530416
• Goss Effects of liarozole fumarate (R85246) in combination with tamox. on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model. BMC Cancer 2007 PMID: 17266767
• Van Wauwe Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J.Pharmacol.Exp.Ther. 1992 PMID: 1374473

Product Documents for Liarozole dihydrochloride